Does a GLP-1 affect blood pressure differently in Black women?

# Does a GLP-1 affect blood pressure differently in Black women?

If you are a Black woman weighing one of these medications, blood pressure is a fair thing to ask about, because hypertension shows up earlier and more often in your community. The honest answer is that these medicines tend to lower blood pressure modestly for the people studied, but the research has not yet been built to tell us whether that effect is any different by race. This article walks through what is solid, what is thin, and what that means for the questions you bring to your clinician.

Key takeaways

Dr. Linda's take

I want to answer this the way I would want it answered for me, which means separating two true things that often get blended together. One is that these medicines are associated with a modest drop in blood pressure, and that appears to travel with the weight loss rather than being a separate magic effect. The other is that Black women carry a heavier baseline burden of high blood pressure, for reasons that are structural and clinical, not personal.

Where people go wrong is assuming those two facts combine into a known, race-specific number. They do not. The trials that built this evidence base did not enroll enough Black women to measure a distinct blood-pressure effect with confidence, so anyone quoting you a precise "in Black women it lowers pressure by X" is going beyond the data. What I can tell you is that the general effect looks real and gentle, that no analysis has found the response flipping upside down by race, and that the honest gaps are worth naming out loud. If you want to see whether treatment is even a fit for your situation, our eligibility quiz is one place to begin.

Why does blood pressure matter more here?

Because the starting point is different. High blood pressure is more common, and it arrives earlier, in Black communities, and that shapes the whole conversation about any weight-related medication.

The prevalence of hypertension is higher in both middle-aged and older African Americans compared with non-Hispanic whites. The scale of it is striking when you look at lifetime risk. Three in four African American men and women are likely to develop high blood pressure by the age of 55, compared with 40 percent of white women in the same age range. This is not about anything a person did or did not do. It reflects a mix of structural and clinical factors, and it is exactly why blood pressure deserves specific attention in this group rather than a footnote. It is part of a wider pattern in which Black and Latina women carry a higher baseline risk of obesity and diabetes as well.

How do these medicines affect blood pressure?

Now the reassuring part, held at the right size. The effect is real, it is modest, and it seems tied to weight loss.

In an individual patient data meta-analysis of three large semaglutide trials, the difference in systolic blood pressure change between the treatment and placebo groups was about minus 4.95 mmHg overall. A shift of that size is not trivial in a body, because a systolic blood pressure reduction of about 5 mmHg is generally considered clinically significant. The other main medicine in this class tells a similar story when researchers measured it carefully over a full day. In the SURMOUNT-1 ambulatory blood pressure substudy, each dose of tirzepatide reduced 24-hour systolic blood pressure at 36 weeks compared with placebo. In that same substudy, tirzepatide lowered 24-hour systolic blood pressure by about 7.4 mmHg at the 5 mg dose, 10.6 mmHg at the 10 mg dose, and 8.0 mmHg at the 15 mg dose compared with placebo.

The mechanism matters for how you read this. Mediation analyses indicated that changes in ambulatory systolic blood pressure were partially mediated by weight changes, with about 70 percent of the effect mediated by weight. In plain terms, most of the blood-pressure benefit appears to ride along with the weight change, which is a useful thing to understand rather than expecting the medication to act as a blood pressure drug on its own.

Is there data specific to Black women?

This is the crux, and it is where honesty has to lead. The short version is that the race-specific blood-pressure data does not really exist yet, because the trials were not built to produce it.

A 2024 systematic review of 27 randomized trials of GLP-1 medicines for obesity found that White participants made up about 79 percent of those enrolled, while Black participants made up about 9 percent and Hispanic participants about 22 percent. When a subgroup is that small, it is hard to detect a real difference in something like blood pressure even if one exists, and the absence of a signal is not proof of sameness. This representation gap runs through the whole field, including whether Black and Latina women were included in these weight-loss trials at all.

What researchers have been able to check is reassuring as far as it goes. In a post hoc analysis of the STEP 1 and STEP 3 trials, the treatment effect of semaglutide was statistically significant and clinically relevant across all racial and ethnic subgroups. That same analysis found there were no significant interactions between the treatment effect and race or ethnicity. Read plainly, the medicine worked across the groups studied and nothing pointed to a fundamentally different response by race. What is still missing is large, deliberately diverse research designed to measure the blood-pressure effect in Black women with real statistical power. This is the same evidence gap that shapes whether these medications work as well for Black and Latina women more broadly.

What can you ask your clinician?

You can turn all of this into sharper questions. You might ask how your current blood pressure and any blood pressure medications you take would be monitored if you started treatment, since a modest drop in pressure can matter when you are already being treated for hypertension. You might ask what the plan is for checking blood pressure over the first few months, and what numbers would prompt a change. And you can name the evidence gap directly, asking your clinician to distinguish between what is known for the broad population and what is genuinely uncertain for Black women specifically. None of this tells you what to do. It helps you walk in informed rather than guessing.

Frequently asked questions

Does a GLP-1 lower blood pressure more or less in Black women?

There is no reliable data showing a different-sized blood-pressure effect by race. The trials that built the evidence enrolled mostly White participants, so the effect in Black women specifically has not been measured with confidence. Where researchers looked, the treatment effect was consistent across racial and ethnic subgroups, but the subgroups were small.

How much do these medicines actually lower blood pressure?

Modestly. In a meta-analysis of three large trials of one medicine in this class, systolic blood pressure fell by about 4.95 mmHg more than with placebo, and a reduction of about 5 mmHg is generally considered clinically significant. In a separate substudy of the other main medicine, round-the-clock systolic pressure fell further versus placebo, with larger drops at higher doses.

Why does high blood pressure matter more for Black women?

Because it is more common and starts earlier. The prevalence of hypertension is higher in African Americans than in non-Hispanic whites, and three in four African American men and women are likely to develop high blood pressure by age 55. That heavier baseline is why blood pressure deserves specific attention here.

Is the blood-pressure benefit separate from weight loss?

Mostly not. Mediation analysis found that about 70 percent of the systolic blood-pressure effect was mediated by weight change, so most of the benefit appears to travel with the weight loss rather than being a separate action of the drug.

References

1. Kennedy C, et al. (2024). Semaglutide and blood pressure: an individual patient data meta-analysis. European Heart Journal. https://pubmed.ncbi.nlm.nih.gov/39217502/ (Accessed 2026-07-24).
2. Kennedy C, et al. (2024). Semaglutide and blood pressure: an individual patient data meta-analysis. European Heart Journal (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC11458150/ (Accessed 2026-07-24).
3. de Lemos JA, et al. (2024). Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index >=27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. Hypertension. https://pmc.ncbi.nlm.nih.gov/articles/PMC10956672/ (Accessed 2026-07-24).
4. National Heart, Lung, and Blood Institute (2018). Most African Americans have high blood pressure before age 55. NHLBI, NIH. https://www.nhlbi.nih.gov/news/2018/most-african-americans-have-high-blood-pressure-age-55 (Accessed 2026-07-24).
5. Lackland DT (2014). Racial Differences in Hypertension: Implications for High Blood Pressure Management. The American Journal of the Medical Sciences. https://pmc.ncbi.nlm.nih.gov/articles/PMC4108512/ (Accessed 2026-07-24).
6. Representation of racialised and ethnically diverse populations in randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis (2024). PubMed. https://pubmed.ncbi.nlm.nih.gov/39608857/ (Accessed 2026-07-24).
7. Rubino D, et al. (2024). Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials. Obesity (Silver Spring). https://pubmed.ncbi.nlm.nih.gov/38932728/ (Accessed 2026-07-24).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-24.*